Skip to main content

Table 2 Comparison of clinical and biochemical parameters at baseline and 24 weeks

From: Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case–control study

 

Teneligliptin (n = 22)

Sitagliptin (n = 23)

P1 value

P2 value

Baseline

24 weeks

Baseline

24 weeks

HbA1c % (NGSP)

8.1 ± 1.4

8.0 ± 1.2

8.0 ± 1.7

7.9 ± 1.4

0.27

0.39

Fasting glucose (mg/dL)

161.5 ± 49.7

157.7 ± 31.7

150.0 ± 26.3

161.7 ± 33.6

0.8

0.19

C-peptide (ng/mL)

1.8 ± 0.9

2.0 ± 0.6

2.5 ± 1.0

2.5 ± 1.1

0.32

0.33

SBP (mmHg)

133.3 ± 13.4

132.4 ± 14.2

139.1 ± 22.9

131.4 ± 16.8

0.79

0.06

DBP (mmHg)

76.1 ± 11.0

74.0 ± 10.9

79.3 ± 17.0

75.4 ± 12.8

0.5

0.07

LDL-C (mg/dL)

107.1 ± 21.3

105.3 ± 19.4

98.2 ± 21.5

98.7 ± 21.6

0.71

0.91

HDL-C (mg/dL)

53.4 ± 13.2

50.7 ± 12.0

55.5 ± 16.8

50.1 ± 9.1

0.12

0.06

TG (mg/dL)

120.3 ± 41.3

129.3 ± 60.1

156.1 ± 99.9

149.0 ± 70.2

0.51

0.61

eGFR (ml/min−1/1.73 m2)

43.5 ± 15.8

42.8 ± 16.7

39.6 ± 15.9

39.2 ± 16.2

0.36

0.77

Urinary albumin (mg/g Cre)

141.0 (93.5–299.5)

176.0 (84.5-268.0)

141.5 (67.0–729.3)

165.5 (52.8-546.0)

0.58

0.32

Log urinary albumin (mg/g Cre)

2.3 ± 0.5

2.3 ± 0.5

2.3 ± 0.6

2.3 ± 0.6

0.73

0.25

Urinary 8-OHdG (ng/mg Cre)

7.1 ± 4.9

5.4 ± 2.9

6.4 ± 1.5

7.4 ± 2.1

0.03*

0.1

Urinary L-FABP (µg/g Cre)

25.7 (6.3–118.0)

14.5 (7.0–64.9)

48.2 (7.2–91.9)

55.0 (9.6–110.8)

0.02*

0.22

Urinary 8-isoprostane (pg/mgCr)

199.0 (151.5–424.0)

297.0 (212.5–440.0)

258.0 (227.0–429.0)

353.0 (301.0–578.0)

0.06

0.01*

  1. Data are mean ± SD or median and interquartile range
  2. SBP systolic blood pressure, DBP diastolic blood pressure, LDL-C low-density lipoprotein cholesterol, HDL high-density lipoprotein cholesterol, TG triglycerides, eGER estimated glomerular filtration rate, 8-OHdG 8-hydroxy-2′-deoxyguanosine, L-FABP liver-type fatty acid binding protein
  3. * P1 value: <0.05, comparison of respective data between baseline and after 24 weeks treatment with teneligliptin
  4. * P2 value: <0.05, comparison of respective data between baseline and after 6 month treatment with sitagliptin